Enzo Life Sciences BML-282 (5mg)
Novel inhibitor of ubiquitin C-terminal hydrolase L1 (IC50 = 0.81 µM). It displays 21-fold greater selectivity over UCH-L3 (IC50 = 17 µM). Alternative name: N-(3,4-Dichlorobenzyl)-5-bromoisatin O-acetyloxime. Purity: ≥98% (TLC). Solubility: Soluble in DMSO (5mg/ml with warming) or dimethyl formamide (10mg/ml with warming). Long Term Storage: -20°C.